NEA 15 Amends 13D Filing for OnKure Therapeutics
Ticker: OKUR · Form: SC 13D/A · Filed: Oct 8, 2024 · CIK: 1637715
Sentiment: neutral
Topics: ownership-change, sec-filing, amendment
TL;DR
NEA 15 updated its 13D filing for OnKure Therapeutics. Ownership details TBD.
AI Summary
New Enterprise Associates 15, L.P. (NEA 15) and its affiliated group, including Anthony A. Florence, Jr., Forest Baskett, Mohamad H. Makhzoumi, and Scott D. Sandell, have filed an amendment to their Schedule 13D concerning OnKure Therapeutics, Inc. The filing, dated October 8, 2024, indicates a change in beneficial ownership, though specific new holdings or percentage changes are not detailed in this excerpt. The group previously held a significant stake in the company.
Why It Matters
This amendment signals a potential shift in the ownership structure or investment strategy of a significant shareholder in OnKure Therapeutics, which could impact the company's future direction and stock performance.
Risk Assessment
Risk Level: medium — Amendments to Schedule 13D filings often precede significant corporate actions or changes in control, introducing uncertainty.
Key Players & Entities
- New Enterprise Associates 15, L.P. (company) — Filing entity
- OnKure Therapeutics, Inc. (company) — Subject company
- Anthony A. Florence, Jr. (person) — Group member
- Forest Baskett (person) — Group member
- Mohamad H. Makhzoumi (person) — Group member
- Scott D. Sandell (person) — Group member
- NEA 15 GP, LLC (company) — Group member
- NEA PARTNERS 15, L.P. (company) — Group member
FAQ
What specific changes in beneficial ownership are detailed in this amendment?
This excerpt does not specify the exact changes in beneficial ownership, only that an amendment to the Schedule 13D has been filed.
Who are the members of the group filing this amendment?
The group includes New Enterprise Associates 15, L.P., NEA 15 GP, LLC, NEA PARTNERS 15, L.P., Anthony A. Florence, Jr., Forest Baskett, Mohamad H. Makhzoumi, and Scott D. Sandell.
What is the subject company of this filing?
The subject company is OnKure Therapeutics, Inc.
When was this amendment filed with the SEC?
This amendment was filed on October 8, 2024.
What was the former name of OnKure Therapeutics, Inc.?
The former name of OnKure Therapeutics, Inc. was Reneo Pharmaceuticals, Inc., with a name change date of March 25, 2015.
Filing Stats: 1,955 words · 8 min read · ~7 pages · Grade level 9.6 · Accepted 2024-10-08 19:34:57
Key Financial Figures
- $0.0001 — created Class A common stock, par value $0.0001 per share, and the change in the number
Filing Documents
- nea15-onkure_18889.htm (SC 13D/A) — 112KB
- 0001072613-24-000769.txt ( ) — 114KB
Purpose
Item 4. Purpose of Transaction . Not applicable. CUSIP No.75974E103 13D Page 3 of 9 Pages Item 5. Interest in Securities of the Issuer. As of October 4, 2024, each of the Reporting Persons ceased to beneficially own five percent (5%) or more of the Issuer’s Common Stock. This Amendment No. 2 was triggered solely due to the transactions (the “Transactions”) contemplated by that certain agreement and plan of merger by and among the Issuer, Radiate Merger Sub I, Inc., a Delaware corporation, Radiate Merger Sub II, LLC, a Delaware limited liability company, and legacy OnKure, Inc., a Delaware corporation, as described in further detail in the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 13, 2024, including the reclassification of the Issuer’s Common Stock into the Issuer’s newly created Class A common stock, par value $0.0001 per share, and the change in the number of outstanding shares of the Issuer as a result of the Transactions. Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer. Not applicable. Item 7. Material to Be Filed as Exhibits. Exhibit 1 – Agreement regarding filing of joint Schedule 13D. Exhibit 2 – Power of Attorney regarding filings under the Securities Exchange Act of 1934, as amended . CUSIP No.75974E103 13D Page 4 of 9 Pages SIGNATURE After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct. EXECUTED this 8 th day of October, 2024. NEW ENTERPRISE ASSOCIATES 15, L.P. By: NEA PARTNERS 15, L.P. General Partner By: NEA 15 GP, LLC General Partner By: * Anthony A. Florence, Jr. Managing Partner and Co-Chief Executive Officer By: * Mohamad Makhzoumi Managing Partner and Co-Chief Executive Officer NEA PARTNERS 15, L.P. By: NEA 15 GP